Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

BACKGROUND: Acute myeloid leukaemia (AML) is treated with intensive induction chemotherapy (IT) in medically fit patients. In general, obesity was identified as a risk factor for all-cause mortality, and there is an ongoing debate on its impact on outcome and optimal dosing strategy in obese AML pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Enßle, Julius C., Wolf, Sebastian, Scheich, Sebastian, Weber, Sarah, Kramer, Michael, Ruhnke, Leo, Schliemann, Christoph, Mikesch, Jan-Henrik, Krause, Stefan, Sauer, Tim, Hanoun, Maher, Reinhardt, Hans Christian, Kraus, Sabrina, Kaufmann, Martin, Hänel, Mathias, Fransecky, Lars, Burchert, Andreas, Neubauer, Andreas, Crysandt, Martina, Jost, Edgar, Niemann, Dirk, Schäfer-Eckart, Kerstin, Held, Gerhard, Kaiser, Ulrich, Wass, Maxi, Schaich, Markus, Müller-Tidow, Carsten, Platzbecker, Uwe, Baldus, Claudia D., Bornhäuser, Martin, Röllig, Christoph, Serve, Hubert, Steffen, Björn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539505/
https://www.ncbi.nlm.nih.gov/pubmed/37542108
http://dx.doi.org/10.1038/s41416-023-02362-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539505/
https://www.ncbi.nlm.nih.gov/pubmed/37542108
http://dx.doi.org/10.1038/s41416-023-02362-3

Ejemplares similares